BioCryst Pharmaceuticals (NASDAQ:BCRX) Sets New 1-Year High – Here’s What Happened

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $9.40 and last traded at $9.36, with a volume of 600478 shares trading hands. The stock had previously closed at $9.05.

Analyst Ratings Changes

Several brokerages recently issued reports on BCRX. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Needham & Company LLC increased their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Barclays upped their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. JMP Securities reiterated a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Finally, Evercore ISI upped their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $15.50.

BioCryst Pharmaceuticals Stock Performance

The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -15.39 and a beta of 1.75. The company has a 50-day moving average price of $7.94 and a 200-day moving average price of $7.81.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $33,000. Venturi Wealth Management LLC acquired a new position in BioCryst Pharmaceuticals during the fourth quarter worth approximately $46,000. R Squared Ltd purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $48,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,322 shares during the period. Finally, KBC Group NV grew its position in shares of BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 4,537 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.